Letter to the edior

Retina

Volumn 28, Issue 6, 2008, Pages 911-912

  Hedaya, Joshua ^a   Freeman, William R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANAMNESIS; DRUG EFFECT; DRUG EFFICACY; HUMAN; LETTER; PHOTODYNAMIC THERAPY; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; ANGIOID STREAK; DRUG ANTAGONISM; FLUORESCENCE ANGIOGRAPHY; INJECTION; NOTE; OPTICAL COHERENCE TOMOGRAPHY; PSEUDOXANTHOMA ELASTICUM; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANGIOID STREAKS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; PSEUDOXANTHOMA ELASTICUM; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 67749111675     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181733746     Document Type: Letter

References (1)

1. Bhatnagar P, Spaide RF, Takahashi BS, et al. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2007;27:846-850.